Pediatric clinical trial profile for COVID-19 at ClinicalTrials.gov: a systematic review

M. Covolan, Luiza Tsuruda, D. Silva, David Barbosa, R. Pasa, K. Kavalco, F. Menegídio
{"title":"Pediatric clinical trial profile for COVID-19 at ClinicalTrials.gov: a systematic review","authors":"M. Covolan, Luiza Tsuruda, D. Silva, David Barbosa, R. Pasa, K. Kavalco, F. Menegídio","doi":"10.25060/residpediatr-2021.v11n2-614","DOIUrl":null,"url":null,"abstract":"INTRODUCTION: COVID-19 is an extremely serious infectious disease. However, few studies have focu-sed on the drug treatment of pediatric patients affected by COVID-19. OBJECTIVE: Thus, this study conducted a review of clinical trials registered in the Clinical Trials database on drug treatment in pe-diatric patients with COVID-19. METHODS: A systematic search was conducted in the Clinical Trials database (https://clinicaltrials.gov/) using the web tracking technique to collect registered clinical tri-als that conducted drug treatment in pediatric patients aged 0 to 17 years. After the drugs used were identified, their dosage and other pertinent information were obtained from the DrugBank databases (https://go.drugbank.com) and the DrugBase (https://www.drugbase.de). RESULTS: Eight clinical trials were found in the research, classified as completed and 34 in progress, aimed at pediatric patients. The United States was the country that most research involving the drug use in patients with pedia-tric COVID-19. Hydroxychloroquine was the most observed drug in the treatment of pediatric pa-tients, followed by remdesivir. An increase in phase 3 and randomized trials was also observed among ongoing research when compared to completed research. CONCLUSION: Compared to adults, pedia-tric COVID-19 has distinct treatment needs. Thus, it is important to complete the clinical trials de-scribed in the present study, in addition to more randomized clinical trials, before any therapy or other objects related to the clinical management processes for COVID-19 can be properly recom-mended and applied in pediatric treatment.","PeriodicalId":338092,"journal":{"name":"Residência Pediátrica","volume":"110 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Residência Pediátrica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25060/residpediatr-2021.v11n2-614","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

INTRODUCTION: COVID-19 is an extremely serious infectious disease. However, few studies have focu-sed on the drug treatment of pediatric patients affected by COVID-19. OBJECTIVE: Thus, this study conducted a review of clinical trials registered in the Clinical Trials database on drug treatment in pe-diatric patients with COVID-19. METHODS: A systematic search was conducted in the Clinical Trials database (https://clinicaltrials.gov/) using the web tracking technique to collect registered clinical tri-als that conducted drug treatment in pediatric patients aged 0 to 17 years. After the drugs used were identified, their dosage and other pertinent information were obtained from the DrugBank databases (https://go.drugbank.com) and the DrugBase (https://www.drugbase.de). RESULTS: Eight clinical trials were found in the research, classified as completed and 34 in progress, aimed at pediatric patients. The United States was the country that most research involving the drug use in patients with pedia-tric COVID-19. Hydroxychloroquine was the most observed drug in the treatment of pediatric pa-tients, followed by remdesivir. An increase in phase 3 and randomized trials was also observed among ongoing research when compared to completed research. CONCLUSION: Compared to adults, pedia-tric COVID-19 has distinct treatment needs. Thus, it is important to complete the clinical trials de-scribed in the present study, in addition to more randomized clinical trials, before any therapy or other objects related to the clinical management processes for COVID-19 can be properly recom-mended and applied in pediatric treatment.
ClinicalTrials.gov上针对COVID-19的儿科临床试验概况:一项系统综述
简介:COVID-19是一种极其严重的传染病。然而,很少有研究关注COVID-19患儿的药物治疗。目的:因此,本研究对临床试验数据库中注册的儿科COVID-19患者药物治疗的临床试验进行了综述。方法:采用网络追踪技术系统检索临床试验数据库(https://clinicaltrials.gov/),收集已注册的0 - 17岁儿科患者进行药物治疗的临床试验。在确定使用的药物后,从DrugBank数据库(https://go.drugbank.com)和DrugBase数据库(https://www.drugbase.de)获取其剂量和其他相关信息。结果:本研究共发现8项临床试验,其中完成试验34项正在进行中,均针对儿科患者。美国是涉及小儿COVID-19患者用药研究最多的国家。羟基氯喹是儿童患者治疗中观察到最多的药物,其次是瑞德西韦。与已完成的研究相比,正在进行的研究中3期和随机试验的数量也有所增加。结论:与成人相比,小儿COVID-19具有明显的治疗需求。因此,除了更多的随机临床试验外,重要的是完成本研究中描述的临床试验,然后才能正确推荐和应用与COVID-19临床管理流程相关的任何治疗或其他对象。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信